Feasible To Treat Hepatitis C At Scale, Study

A decentralized, algorithm-based public health model helped cure over 90 percent of patients with hepatitis C virus infections in Punjab, India.

Generic HepC Meds In India Really Pay Off

Using generic drugs to treat hepatitis C in India would increase patients' life expectancy by more than eight years and reduce lifetime healthcare costs by US$1,300.

Dollars And Drugs

SMU Professor Locknie Hsu studies how trade deals affect the public’s access to affordable medicines and healthcare.

India’s First Lady Of Biotech

Ms. Kiran Mazumdar-Shaw, chairman and managing director of Biocon Limited, talks to Asian Scientist Magazine about the challenges faced by biotech companies in Asia.

Eisai Acquires Chinese Generics Company Liaoning TianYi

The acquisition of Liaoning gives Eisai a foothold in China's generics sector which accounts for 80 percent of the country's pharmaceutical market.

Cipla Launches Hepcvir-L For HepC Genotype 1 Patients

Hepcvir-L will be provided to patients in India at the fraction of the cost of branded Ledipasvir-Sofosbuvir under a licensing agreement with Gilead Sciences Inc.

Teva & Takeda Enter Joint Venture For Generics In Japan

Asia's largest pharmaceutical company has entered a partnership with Teva to provide generic drugs to Japan.

Cipla Expands Into The US With InvaGen & Exelan Acquistions

Cipla grows its portfolio by acquiring InvaGen and Exelan Pharmaceuticals, stretching its reach to the US market.

Daiichi Sankyo Sells Shares Of Sun Pharma

Rocked by FDA warnings and fines, Sun Pharma has been dropped by Japanese pharmaceutical giant Daiichi Sankyo.

Generic Hepatitis Drug Launched In India As Hepcvir

Generics manufacturer Cipla has been granted the license to produce Sofosbuvir in India under the brand name Hepcvir.